HiTech Health is thrilled to announce its partnership with VascVersa, a trailblazer in regenerative medicine focusing on pioneering cell therapies that significantly enhance vascular regeneration and repair. Originating from Queen’s University Belfast, VascVersa is a dynamic spin-out backed by over two decades of meticulous research. This extensive study has culminated in the development of innovative cell therapies that stand at the forefront of medical science. Their flagship product, ANGICYTE™ Technology, is a revolutionary cell therapy approach aimed at blood vessel regeneration. This advanced treatment is designed to stimulate the formation of new blood vessels, which in turn improves blood supply to affected areas and facilitates long-term healing and recovery.
This cutting-edge cell therapy boasts a wide range of potential applications, promising transformative impacts across various ischaemic diseases. The ANGICYTE™ Technology harnesses the power of targeted cell therapy to address the root causes of vascular deficiencies, thereby enhancing patient outcomes and quality of life. The HiTech Health team is enthusiastic about the prospects of this collaboration with VascVersa. Together, they aim to push the boundaries of what’s possible in cell therapy, advancing these transformative treatments through clinical trials to real-world application. By utilizing ANGICYTE™ Technology, HiTech Health is committed to developing effective treatments that offer hope and healing to patients suffering from vascular issues.
Learn more about our cell and gene therapy services by clicking here
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under Ireland’s National Development Plan (NDP) in 2018. On Thursday 23rd November, Ireland’s Minister for Enterprise, Trade and Employment, Simon Coveney TD, Minister for Further and Higher Education, Research, Innovation and Science, Simon Harris TD and the Minister of State for Trade Promotion, Digital and Company Regulation, Dara Calleary TD, today announced funding of a further €58.8 million to 12 new projects under the DTIF.
The purpose of the fund is to drive collaboration between Ireland’s world-class research base and industry as well as facilitating enterprises to compete directly for funding in support of the development and adoption of these technologies. The aim is to support investment in the development and deployment of disruptive technologies and applications on a commercial basis.
HiTech Health (Déantúsaíocht Sláinte Hitech Teoranta), University of Galway (UG) and Odyssey Validation Consultants Ltd have been awarded €6,579,772 as part of the DTIF for a CellConnect project. CellConnect will capture data from every stage of the cell manufacturing process and empower Ireland’s cell-based therapeutic manufacturing revolution by developing disruptive methods to automate processes and transport cell products.
Dr Brian Harrison, Managing Director of HiTech Health, said “We are delighted to have been given this prestigious DTIF award and look forward to working with our partners, the Duffy Laboratory in University of Galway and Odyssey Validation Consultants to bring this exciting CellConnect project to reality. Cell Therapies really are life changing medicines and Hitech Health are currently working with several client companies who are bringing new therapies to patients many of whom suffer from rare diseases. This CellConnect platform will provide a significant step forward in the automation of processes, many of which are currently paper based. This project will also build capability in Ireland in this rapidly growing area of ‘Advanced’ medicines which is leading to treatments that can transform patients’ lives”.
Hitech Health is delighted to be attending Advanced Therapies Integrates in Stevenage, England on the 30th November. This event aims to drive the translation of cutting-edge research and disruptive innovation into the wide-spread adoption of Advanced Therapies, delivering improved patient outcomes and a revolution in healthcare economics. Advanced Therapies Integrates will bring together innovators, regulators, supply chain partners, equipment & technology providers, academia, industry associations, together with a wide array of government funding bodies and government supported pharma-focused initiatives.
The genomics revolution and other advances have led to the emergence of highly effective, but extremely complex therapeutics, with cell and gene therapies, regenerative medicines and tissue therapies now transforming the prospects of patients and healthcare providers around the globe. As a full service CDMO for advanced medicines, Hitech Health is well positioned to work closely with you to support the successful development and manufacturing of new therapies.
To learn more about our cell and gene therapy services by clicking here
Afortiori Development and HiTech Health Forge an Important Collaboration to Support the Clinical Research and Product Development of Groundbreaking Cell and Gene Therapies.
Galway, November 9, 2023 – Afortiori Development, a premier full-service Clinical Research Organisation, is thrilled to announce its latest partnership with HiTech Health, a leading Contract Development and Manufacturing Organisation (CDMO) for Advanced Therapy Medicinal Products (ATMP) including Cell and Gene Therapies (CGT) (Europe/UK/Ireland/US). This strategic alliance aims to provide an integrated suite of services to companies conducting research in the ATMP and CGT areas. The two companies believe that by seamlessly integrating clinical trial expertise with cutting-edge product development and manufacturing capabilities, this will provide the calibre of service required by companies conducting research, ensuring that their clinical research journey is enhanced overall.
Afortiori Development’s unwavering commitment to providing expert, flexible and economically viable clinical trial design and clinical trial management services perfectly complements HiTech Health’s extensive knowledge and expertise in product development, manufacturing and supply chain. By joining forces, these industry pioneers are in a strong position to deliver unparalleled support, enabling clients to optimise their clinical research processes, enable faster trial start up and drive ongoing support of their revolutionary products while research is in progress.
“Our approach has to evolve to deliver the cutting-edge services that clients innovating in the advanced therapy space require. Aligning our services with companies like HiTech Health means that we can ensure timely and high-quality supply of products required for trial needs. A critical requirement for many of these advanced cell and gene therapies,” emphasised Dr Nicola Wall, CEO at Afortiori Development. “We understand the paramount importance of obtaining high-quality IMP that is available when needed for researchers and meets the quality standards. Through our collaboration with HiTech Health, we are poised to provide unmatched expertise and support to our clients running these types of clinical trials.”
Afortiori Development and HiTech Health represent a combined team of seasoned experts who work closely with clients, offering flexible, scalable, and tailored solutions to each trial’s specific needs. Throughout the entire process, these industry leaders remain dedicated advocates for their clients, ensuring they benefit from the optimal clinical trial delivery services that generate actionable insights for safety, efficacy and regulatory compliance.
“The success of the clinical trial is deeply affected by the timely availability of high quality products, supported by the right processes, systems, and experts,” added Dr Brian Harrison, CEO of HiTech Health. “Through our collaboration with Afortiori Development, clients can leverage the combined strength of a team that knows exactly what needs to happen and when, ensuring our projects meet timelines and expectations overall.”
Both companies encourage clients to explore the combined team’s extensive knowledge and capabilities in trial design, trial delivery operational planning, product development and Chemistry Manufacturing and Controls (CMC) operational activities. With HiTech Health’s state-of-the-art laboratories and GMP manufacturing facilities equipped for process and analytical development, clients can rely on their cutting-edge cell and gene therapy expertise to accelerate product development timelines.
Afortiori Development and HiTech Health invite clients and industry professionals to get in touch to discuss their current and future needs. Engaging with their dedicated teams of experts will unlock new possibilities and propel clients towards success on this exhilarating path.
About Afortiori Development:
Afortiori Development is a full-service Clinical Research Organisation specializing in the design and management of clinical trials and post-market clinical follow-up studies. With a flexible, scalable, and client-centric approach, Afortiori Development provides critical support to clients to facilitate the right clinical trial.
About HiTech Health:
HiTech Health is a CDMO focused on product development and GMP manufacturing of advanced medicines including cell and gene therapy products.. Their specialized knowledge and state-of-the-art facilities enable efficient and cost-effective development and manufacturing solutions for clients.
To learn more about our cell and gene therapy services by clicking here
